These findings suggest that binding-defective CRLF1 variants have the potential to serve as tumor-specific polypeptide drugs, enhancing chemotherapy effectiveness as adjuvant therapy in ovarian cancer (Fig. 8H). This evidence concerns the gene CRLF1 and neoplasm.